ATC

Is TECELRA an option for me?

TECELRA is for certain adults† with advanced synovial sarcoma and requires testing before treatment

TECELRA may be right for you if you have:

Icon shape Icon of an IV bag

Received prior
chemotherapy

Chemotherapy is a type of systemic therapy, which is a treatment that travels through the bloodstream to affect cells all over the body. You may have tried one of the following kinds of chemotherapy:

  • Ifosfamide
  • Doxorubicin
  • Trabectedin
  • Dacarbazine
  • Gemcitabine

You also may have tried a non-chemotherapy systemic therapy, like pazopanib, in addition to chemotherapy.

Icon shape Icon of a medical chart and a DNA strand

A specific
genetic profile

This genetic profile means that your cells make a specific version of the HLA-A*02 protein. HLA proteins help your T cells respond and bind to cancer cells. In order to receive TECELRA, you need HLA-A*02:01P, HLA-A*02:02P, HLA-A*02:03P, or HLA-A*02:06P, and must not have HLA-A*02:05P.

Icon shape Icon of a magnifying glass looking at a tumor

A tumor that expresses a certain biomarker

This certain biomarker is called MAGE-A4, which is a protein found in some synovial sarcoma tumors. This is the protein TECELRA is designed to recognize as an abnormal or dangerous substance in the body.

Photo image of an adult female patient speaking with doctor and nurse in a hospital setting, with an engineered mechanical yellow and magenta butterfly on her shoulder

Not an actual patient or healthcare providers.

Your doctor may recommend testing to see if TECELRA is right for you

Those tests include:

Icon shape Icon of a test tube

A blood test

This test will check to see if you have an eligible genetic profile. Your cells need to express a certain HLA protein‡—or biomarker—for TECELRA to work in your body. There is also an HLA marker that could make you ineligible for TECELRA.

Icon shape Icon of a tumor sample

A tumor tissue test

This test will check for a biomarker called MAGE-A4, which is the protein TECELRA-engineered T cells are designed to target.

Talk to your doctor about testing for TECELRA today to see if it might be right for you dots
Not an actual patient.

HLA=human leukocyte antigen; MAGE=melanoma-associated antigen.

 †

TECELRA is for people with certain HLA-A*02 types whose tumor expresses the MAGE-A4 antigen.

‡

Positive for HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P, and negative for HLA-A*02:05P.

want to learn more?

Discover how TECELRA works arrow icon See the TECELRA study data arrow icon EXPLORE THE TECELRA
treatment journey arrow icon

INDICATION and IMPORTANT SAFETY INFORMATION

What is TECELRA?

TECELRA is a medicine, called a genetically modified autologous T cell immunotherapy, that is used to treat synovial sarcoma. It is used when other kinds of treatment do not work. TECELRA is different from other cancer medicines because it is made from your own white blood cells that are made to recognize and attack your cancer cells. Your healthcare provider will perform tests to see if TECELRA is right for you. TECELRA is approved based on patient response data. Additional data are needed to confirm the clinical benefit of TECELRA. It is not known if TECELRA is safe and effective in children.

Please see Medication Guide, including Important Warning.

IMPORTANT SAFETY INFORMATION

Important Warning: You will likely be in a hospital before and after getting TECELRA. TECELRA may cause side effects that can be severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following: fever (100.4°F/38°C or higher); chills/shivering; difficulty breathing; fast or irregular heartbeat; low blood pressure; fatigue; severe nausea, vomiting, or diarrhea; severe headache; or new skin rash. Tell all your healthcare providers that you were treated with TECELRA.

After getting TECELRA, you will be monitored daily at the healthcare facility for at least 7 days after the infusion. You should plan to stay close to a healthcare facility for at least 4 weeks. Do not drive, operate heavy machinery, or do other activities that could be dangerous for at least 4 weeks after you get TECELRA. Your healthcare provider will do blood tests to follow your progress. It is important that you have your blood tested. If you miss a scheduled appointment for your collection of blood, call your healthcare provider as soon as possible to reschedule.

Before you receive TECELRA, tell your healthcare provider about all the medicines and supplements you take and your medical conditions, including: seizure, stroke, confusion, or memory loss; heart, liver, or kidney problems; low blood pressure; lung or breathing problems; recent or active infection; past infections that can be reactivated following treatment with TECELRA; low blood counts; pregnancy, you think you may be pregnant, or plan to become pregnant; breastfeeding; or taking a blood thinner.

The most common side effects of TECELRA include nausea, vomiting, fatigue, infection, constipation, fever (100.4°F/38°C or higher), abdominal pain, difficulty breathing, decreased appetite, diarrhea, low blood pressure, back pain, fast heart rate, chest pain, general body swelling, low white blood cells, low red blood cells, and low platelets.

You are encouraged to report side effects to the FDA at (800) FDA‑1088 or www.fda.gov/medwatch or to Adaptimmune at 1‑855‑24MYADAP (1-855‑246‑9232).

Please see Medication Guide, including Important Warning.

INDICATION and IMPORTANT SAFETY INFORMATION

What is TECELRA?

TECELRA is a medicine, called a genetically modified autologous T cell immunotherapy, that is used to treat synovial sarcoma. It is used when other kinds of treatment do not work. TECELRA is different from other cancer medicines because it is made from your own white blood cells that are made to recognize and attack your cancer cells. Your healthcare provider will perform tests to see if TECELRA is right for you. TECELRA is approved based on patient response data. Additional data are needed to confirm the clinical benefit of TECELRA. It is not known if TECELRA is safe and effective in children.

Please see Medication Guide, including Important Warning.

IMPORTANT SAFETY INFORMATION

Important Warning: You will likely be in a hospital before and after getting TECELRA. TECELRA may cause side effects that can be severe or life-threatening. Call your healthcare provider or get emergency help right away if you get any of the following: fever (100.4°F/38°C or higher); chills/shivering; difficulty breathing; fast or irregular heartbeat; low blood pressure; fatigue; severe nausea, vomiting, or diarrhea; severe headache; or new skin rash. Tell all your healthcare providers that you were treated with TECELRA.

After getting TECELRA, you will be monitored daily at the healthcare facility for at least 7 days after the infusion. You should plan to stay close to a healthcare facility for at least 4 weeks. Do not drive, operate heavy machinery, or do other activities that could be dangerous for at least 4 weeks after you get TECELRA. Your healthcare provider will do blood tests to follow your progress. It is important that you have your blood tested. If you miss a scheduled appointment for your collection of blood, call your healthcare provider as soon as possible to reschedule.

Before you receive TECELRA, tell your healthcare provider about all the medicines and supplements you take and your medical conditions, including: seizure, stroke, confusion, or memory loss; heart, liver, or kidney problems; low blood pressure; lung or breathing problems; recent or active infection; past infections that can be reactivated following treatment with TECELRA; low blood counts; pregnancy, you think you may be pregnant, or plan to become pregnant; breastfeeding; or taking a blood thinner.

The most common side effects of TECELRA include nausea, vomiting, fatigue, infection, constipation, fever (100.4°F/38°C or higher), abdominal pain, difficulty breathing, decreased appetite, diarrhea, low blood pressure, back pain, fast heart rate, chest pain, general body swelling, low white blood cells, low red blood cells, and low platelets.

You are encouraged to report side effects to the FDA at (800) FDA‑1088 or www.fda.gov/medwatch or to Adaptimmune at 1‑855‑24MYADAP (1-855‑246‑9232).

Please see Medication Guide, including Important Warning.

You are now leaving this site

This link will take you to a third-party site that is not owned by Adaptimmune. Click “OK” if you would like to proceed or click “Cancel” to stay on this site.

OK
Cancel